Thomas Carr Scanlon

Title: Innovations of Thomas Carr Scanlon

Introduction

Thomas Carr Scanlon is an accomplished inventor based in Lebanon, NH (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 2 patents to his name, Scanlon's work focuses on enhancing antimicrobial activity through genetic engineering.

Latest Patents

Scanlon's latest patents include a groundbreaking invention titled "Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections." This invention presents a genetically engineered version of a lysozyme protein that exhibits enhanced antimicrobial activity compared to the wild type enzyme. The engineered enzyme achieves this through a reduced overall electrostatic charge. Such an enzyme is a promising therapeutic candidate for treating microbial or viral infections, especially in cases where infections lead to an accumulation of polyanion inhibitors at the infection site. Respiratory tract infections are highlighted as a specific example where this enzyme could serve as a particularly useful drug.

Career Highlights

Throughout his career, Thomas Carr Scanlon has demonstrated a commitment to advancing medical science through innovative solutions. His work has the potential to significantly impact the treatment of infections, showcasing his expertise in the field of biotechnology.

Collaborations

Scanlon collaborates with notable professionals in his field, including his coworker Karl E Griswold. Their combined efforts contribute to the advancement of therapeutic technologies.

Conclusion

Thomas Carr Scanlon's innovative work in the development of engineered lysozyme variants positions him as a key figure in the biotechnology sector. His contributions are paving the way for new treatments that could improve patient outcomes in the fight against infections.